| GSK’s Cancer Comeback Continues With Data for Multiple Myeloma Drug | Frank Vinluan | 08/23/19 | National |
| Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More | Frank Vinluan | 08/23/19 | National |
| Oncorus Adds $79.5M to Steer Cancer-Fighting Virus to Human Testing | Frank Vinluan | 08/21/19 | Boston |
| Skyhawk Inks Deal With Genentech for Cancer and Neuro Drug Discovery | Frank Vinluan | 07/16/19 | Boston |
| Boston Tech Watch: Cisco, Acacia, Great Hill Partners & GNS Healthcare | Brian Dowling | 07/12/19 | Boston |
| Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More | Alex Lash | 07/12/19 | National |
| Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More | Alex Lash | 06/28/19 | National |
| With $45M Nurix Deal, Gilead Enters Crowded Protein Degradation Field | Frank Vinluan | 06/19/19 | San Francisco |
| Bio Roundup: ASCO Wrap, Bluebird’s EU Tap, CRISPR Baby Risk & More | Alex Lash | 06/07/19 | National |
| Grail’s Cook Steps Down, Former Juno Executive Bishop Named CEO | Frank Vinluan | 06/06/19 | San Francisco |
| Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More | Frank Vinluan | 05/31/19 | National |
| Ideaya and Bicycle Therapeutics IPOs Raise $110M for Cancer Drug R&D | Frank Vinluan | 05/23/19 | San Francisco |
| Vividion Raises $82M to Advance Small Molecule Drugs to the Clinic | Sarah de Crescenzo | 04/30/19 | San Diego |
| It’s Tough to Find Drugs to Bind to RNA: Arrakis Nabs $75M to Help | Frank Vinluan | 04/18/19 | Boston |
| Thwarting Opposition, Bristol Gets Shareholder OK for $74B Celgene Buyout | Ben Fidler | 04/12/19 | New York |
| Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More | Alex Lash | 04/12/19 | National |
| Celgene Files for FDA Approval of Blood Disease Drug | Frank Vinluan | 04/05/19 | New York |
| Bio Roundup: Gottlieb’s Goodbye, AACR Recap, Migraine Drug Fight & More | Frank Vinluan | 04/05/19 | National |
| AACR 2019 Roundup: Notes from a Weekend of Early Stage Cancer Results | Ben Fidler | 04/03/19 | National |
| Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More | Ben Fidler | 03/29/19 | National |
| Amid Acquisition Drama, Celgene Resubmits MS Drug for FDA Approval | Sarah de Crescenzo | 03/25/19 | New York |
| Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More | Alex Lash | 03/22/19 | National |
| Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More | Frank Vinluan | 03/15/19 | National |
| Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track | Frank Vinluan | 03/11/19 | New York |
| The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski | Ben Fidler | 03/11/19 | National |
| Bio Roundup: Pharma in DC, Bristol-Cel in Trouble, Roche Gets A Spark | Ben Fidler | 03/01/19 | National |
| Bristol-Myers’ $74B Celgene Buyout Faces Opposition from Wellington | Frank Vinluan | 02/27/19 | New York |
| Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More | Frank Vinluan | 02/22/19 | National |
| Starboard Ups Bristol-Myers Stake Ahead of Vote on Celgene Deal | Frank Vinluan | 02/20/19 | New York |
| AbbVie Joins Myeloma Race with $90M Deal for Rights to Teneobio Drug | Frank Vinluan | 02/11/19 | San Francisco |
